Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Kerschan-Schindl, K; Haschka, J; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P.
How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?
Horm Metab Res. 2013; 45(9):621-628 Doi: 10.1055/s-0033-1345207
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Dimai Hans Peter
Dobnig Harald
Fahrleitner-Pammer Astrid
Obermayer-Pietsch Barbara

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Bisphosphonates are very frequently prescribed to women suffering from postmenopausal osteoporosis with or without fragility fractures. The present review was aimed to update the available information on the most efficient treatment duration. Studies on bisphosphonate treatment duration were identified by Medline up to January 2013. Bisphosphonates are very effective in the short as well as in the medium-term. However, the optimal duration of use has not been determined yet. Therefore, this review summarizes the long-term effects of bisphosphonates on surrogate parameters of fracture prevention, bone mineral density measurements, and bone turnover markers. An initial treatment period of 3-5 years is recommended. Then, the patient has to be re-evaluated for fracture risk, which depends on fracture status as well as on other health issues. Beyond that, life style factors such as regular physical activity as well as a sufficient intake of calcium and vitamin D or, if necessary supplementation of calcium and/or vitamin D play an essential part in fracture prevention. © Georg Thieme Verlag KG Stuttgart · New York.
Find related publications in this database (using NLM MeSH Indexing)
Biological Markers - metabolism
Bone Remodeling - drug effects
Diphosphonates - administration & dosage Diphosphonates - adverse effects Diphosphonates - pharmacology Diphosphonates - therapeutic use
Female -
Humans -
Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology
Time Factors -
Withholding Treatment -

Find related publications in this database (Keywords)
long-term treatment
bone mineral density
bone mineralization density distribution
fragility fracture
© Med Uni Graz Impressum